FIELD: medicine.
SUBSTANCE: invention relates to biotechnology. Described is antibody, specifically binding domains II and IIIc "ФРФР1" or c complex of fibroblast growth factor type 1 receptor and heparan-sulfate. Claimed is method of tumour growth suppression based on blocking the pathway "human factor of fibroblast growth/human fibroblast growth factor type 1 receptor (domains II and IIIc)", which includes introduction of described antibody. Claimed is conjugate of monoclonal described antibody and contrast substances, intended for application in diagnostics of malignant and other lesions, whose cells express "ФРФР1" in large amount. Also claimed is method of diagnosing malignant neoplasms. Invention makes it possible to block the pathway "factor of fibroblast growth/ fibroblast growth factor type 1 receptor" through binding with domains II and IIIc "ФРФР1", which results in stopping or retarding tumour growth.
EFFECT: invention claims new medications for diagnostics and treatment of diseases associated with excessive proliferation and neovascularisation.
13 cl, 9 dwg, 2 tbl, 3 ex
